Anzeige
Mehr »
Freitag, 09.01.2026 - Börsentäglich über 12.000 News
Steht diese NASDAQ-Biotech-Aktie jetzt vor einer seltenen Kaufgelegenheit?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
134 Leser
Artikel bewerten:
(0)

HealthLynked Corp: HealthLynked Welcomes David Rosal as New Chief Financial Officer

NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare network and services, is delighted to announce the appointment of David Rosal as its new Chief Financial Officer (CFO), effective March 18, 2024. With a distinguished career that spans over two decades, Rosal brings a wealth of experience in financial planning, business scaling, and strategic development, notably from his impactful roles at McDonald's Corporation and Teradata.

During his tenure at McDonald's, Rosal was instrumental in scaling the business through his expertise in financial planning and analysis, business integration, concept development, and due diligence for M&A of major businesses. His leadership significantly contributed to the company's growth and operational efficiency across multiple locations. This experience is directly relevant to HealthLynked's mission to expand its in-network physician and healthcare service network, aiming to transform healthcare into a more connected, efficient, and patient-centric system as well as possible future M&A related to digital healthcare.

At Teradata, as a Senior Industry Expert in CFO Analytics, Rosal led the way in revolutionizing how data is leveraged, particularly in managing large datasets, working directly with large company CFOs to deliver on their wants and needs. His work is set to be a cornerstone for HealthLynked, especially in managing healthcare data to benefit our patient members by providing insights into better care management and understanding disease-related events. This aligns with HealthLynked's commitment to leveraging technology for the betterment of healthcare delivery and patient outcomes.

Michael Dent, M.D., CEO of HealthLynked, expressed his enthusiasm for Rosal's appointment, stating, "David's impressive track record in scaling businesses and his deep expertise in leveraging data to drive financial and operational improvements make him the ideal CFO for HealthLynked. His vision for how technology can enhance healthcare delivery is perfectly in sync with our mission. We are excited to have him on board and look forward to his contributions to our growth and success."

Upon accepting the role, David Rosal shared, "I am thrilled to join HealthLynked, a company at the forefront of transforming healthcare through technology. My career has always been about driving growth and efficiency, and I see immense potential to apply this passion at HealthLynked. I am eager to contribute to expanding our network and enhancing our services, ultimately improving patient outcomes and creating value for our stakeholders."

Rosal's appointment comes at a pivotal time for HealthLynked as it seeks to accelerate its growth and expand its innovative healthcare network. His extensive experience in financial strategy, operational efficiency, and data analytics will be invaluable as HealthLynked continues to evolve and meet the changing needs of the healthcare industry.

A New Era of Financial Transparency and Growth

Dave Rosal plans to introduce more detailed financial modeling to the investor community, highlighting the significant financial opportunity that HealthLynked is delivering with its services. By providing a clearer understanding of HealthLynked's value proposition and growth trajectory, Rosal aims to attract the necessary investments to support the company's innovative approach to healthcare.

HealthLynked's mission goes beyond connecting patients and providers; it aims to create a collective where participation benefits everyone, helping to uncover the causes of cancers and other diseases through shared data and collaborative insights. With Rosal's financial leadership, HealthLynked is poised to make even greater strides in advancing healthcare for all by fostering a community where sharing information leads to better health outcomes.

About HealthLynked

HealthLynked Corp. is dedicated to enhancing healthcare by facilitating the efficient exchange of medical information between patients and providers. Our cloud based HealthLynked Network empowers members to actively manage their healthcare, providing a centralized and secure location for their medical data, including medications, allergies, past surgeries, and personal health records.

Healthcare providers in our network benefit from improved patient care and key insights into their practice operations. Additionally, our preferred providers can leverage HealthLynked's marketing tools to engage both patients, ensuring better patient compliance and optimized scheduling. To avail these services, providers need to claim their profiles and complete the necessary steps to become an in-network provider.

For more about HealthLynked Corp., please visit www.healthlynked.com. Stay connected with HealthLynked on Facebook, Twitter, Instagram, and LinkedIn.

Forward-Looking Statements & Risk Factors

This press release contains forward-looking statements that are not based on historical facts. These statements, as defined by the Private Securities Litigation Reform Act of 1995, may differ from actual results, performance, or achievements. Forward-looking statements involve inherent risks and uncertainties. We advise against placing undue reliance on these statements, which are current only as of the date of this press release.

We are not obligated to publicly update any forward-looking statements unless required by law. Any updates should not be interpreted as an indication of additional updates on the same or other topics. For a detailed understanding of the risks and uncertainties related to our operations, please refer to the "Risk Factors" in our latest Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission, available at www.sec.gov.

HLYK Contact:

Mike Paisan
Director of Investor Relations
IR@healthlynked.com
+1 (800)-928-7144, ext. 123

Wire Service Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com


© 2024 GlobeNewswire (Europe)
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.